CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
chlorthalidone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000514
NCT00000514Phase 3Completed

Systolic Hypertension in the Elderly Program (SHEP)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Apr 15, 2016

In Brief

A Phase 3 clinical trial evaluating chlorthalidone, atenolol, and 1 other intervention for Cardiovascular Diseases and 3 related conditions. Completed.

Detailed Summary

The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

Phase 3CompletedFinished
19841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartJun 1, 1984
Study CompletionOct 1, 1996
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

chlorthalidonedrug

atenololdrug

reserpinedrug